My Size, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on December 27, 2023, specifically the Company's 2023 Annual Meeting of Stockholders. My Size, Inc. is a Delaware corporation with its principal executive offices in Israel, and its common stock trades on the Nasdaq Capital Market under the symbol MYSZ.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Corporate Actions
The following material actions were approved by stockholders at the Annual Meeting:
- Equity Plan Amendment: Stockholders approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares reserved for issuance from 289,000 to 1,040,000 shares.
- Delisting Approval: Stockholders approved the delisting of the Company's common stock from the Tel Aviv Stock Exchange.
- Warrant Issuance Authorization: Stockholders authorized the issuance of shares underlying certain warrants issued pursuant to an Inducement Letter and Engagement Agreement dated August 24, 2023. This issuance may equal or exceed 20% of the common stock outstanding immediately prior to the issuance, in compliance with Nasdaq Listing Rule 5635(d).
- Director Elections: Two Class II directors, Oron Branitzky and Guy Zimmerman, were elected to the Board.
- Compensation Frequency: Stockholders voted to hold future advisory votes on executive compensation every three years.
- Auditor Ratification: The appointment of Somekh Chaikin as the independent public accountant for the fiscal year ending December 31, 2023, was ratified.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures regarding the equity plan amendment and warrant issuance. The Board has formally adopted the three-year frequency for executive compensation advisory votes based on stockholder approval.
Key Facts for Investor Verification
- Verify the impact of the 1,040,000 share increase in the 2017 Equity Incentive Plan on potential future dilution.
- Confirm the specific terms and exercise conditions of the warrants authorized under Proposal 6, which could result in significant dilution (up to 20% of outstanding shares).
- Review the definitive proxy statement filed on November 14, 2023, for detailed terms of the Equity Plan Amendment and warrant agreements.
- Note that the Company is proceeding with delisting from the Tel Aviv Stock Exchange, leaving the Nasdaq Capital Market as its primary listing venue.